California 2019-2020 Regular Session

California Senate Bill SB642

Introduced
2/22/19  
Introduced
2/22/19  
Refer
3/14/19  
Refer
3/14/19  
Refer
4/22/19  
Refer
4/22/19  
Refer
4/24/19  
Refer
4/24/19  
Failed
2/3/20  

Caption

Pharmacy benefit management: Prescription Acquisition and Adjudication Agency.

Impact

The bill significantly impacts existing laws surrounding health care service plans and the role of PBMs. By mandating that these services be handled by the newly created agency, it centralizes authority and accountability, potentially leading to more consistent drug pricing across different healthcare providers. Moreover, it addresses the underlying issue of patients being unaware of less costly medication alternatives. This shift could transform how prescription drugs are handled in the state, aiming for better patient outcomes and cost savings.

Summary

Senate Bill 642, introduced by Senator Stone, addresses the regulation of pharmacy benefit managers (PBMs) in California. The bill seeks to prohibit health care service plans and insurers from entering into or renewing contracts with PBMs after June 30, 2021. It aims to introduce a new entity, the Prescription Acquisition and Adjudication Agency, which will handle pharmacy benefit management services directly, including negotiating pharmaceutical discounts and managing drug formularies. The intent is to streamline processes and potentially lower costs for patients by increasing transparency and competition in the drug pricing market.

Sentiment

The sentiment around SB 642 seems supportive among those who favor healthcare reform and regulating drug prices, as it promises to enhance patient care and reduce drug costs through direct negotiations. However, there may be concerns from insurance companies and existing PBMs regarding the disruption to their current business models. The creation of a government agency to manage these contracts could lead to uncertainties in the market, thus evoking mixed feelings among stakeholders.

Contention

Notable points of contention may arise regarding the feasibility and efficiency of the new agency compared to private PBMs. Questions may also be raised about the bill's implications for healthcare providers who rely on established relationships with PBMs for administering drug coverage and managing costs. Additionally, the bill's requirement for approving new spending through a supermajority in the legislature could be a hurdle to some amendments aimed at refining its provisions.

Companion Bills

No companion bills found.

Similar Bills

CA AB910

Pharmacy benefit management.

CA AB315

Pharmacy benefit management.

CA SB41

Pharmacy benefits.

CA SB966

Pharmacy benefits.

CA AB29

Pharmacy benefit managers.

CA SB1361

Prescription drugs: cost sharing: pharmacy benefit managers.

CT HB05384

An Act Concerning Prescription Drug Costs.

MA H945

To ensure prescription drug cost transparency and affordability